The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
Researchers analyzed medical records of over 2500 Alzheimer’s patients and found most comorbidities, like hypertension and hyperlipidemia, began before diagnosis—except for depression, which was diagnosed afterward.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.